Global Progesterone Injection Supply, Demand and Key Producers, 2026-2032
Description
The global Progesterone Injection market size is expected to reach $ 1150 million by 2032, rising at a market growth of 4.6% CAGR during the forecast period (2026-2032).
Progesterone Injection is typically formulated as an oil-based intramuscular injection, providing systemic progesterone supplementation for the treatment of luteal phase deficiency, luteal support in assisted reproductive technology (ART) cycles, and other clinical settings requiring rapid or stable plasma progesterone levels. It represents a long-established and clinically mature dosage form with widespread historical use. Key upstream inputs include pharmaceutical-grade progesterone API (steroidal hormone), vegetable or synthetic oil vehicles, antioxidants and stabilizers, injectable glass vials, rubber stoppers and aluminum seals, as well as sterile filtration and filling consumables; material costs are relatively low, while sterile manufacturing assurance, oil-phase stability and batch-to-batch consistency are critical quality control elements. Downstream customers mainly include OB-GYN hospitals, fertility clinics, and inpatient and outpatient departments of general hospitals, with continued utilization in regions where alternative dosage forms are less accessible or adherence considerations are secondary. On a due-diligence-grade estimation basis, global nameplate capacity for Progesterone Injection in 2025 is estimated at 0.62 billion units, with actual sales of approximately 0.51 billion units. Driven by extensive generic competition and regional pricing structures, the global average ex-factory price is estimated at USD 1.6 per unit. Overall industry gross margin is estimated at approximately 41%.
The market is characterized by a mature and highly standardized landscape, with supply dominated by multi-regional generic manufacturers and broad product availability. Pricing competition is well established, and clinical use is largely confined to defined settings within obstetrics, gynecology, and reproductive medicine. In many regions, injectable progesterone remains a recognized baseline option, although prescribing decisions have become increasingly selective as treatment pathways evolve. The growing adoption of alternative dosage forms has gradually reshaped the market structure, reducing the central role of injectable therapies without eliminating their presence.
Looking forward, the market is expected to remain broadly stable or experience gradual change rather than significant expansion. Healthcare systems are increasingly prioritizing patient comfort, convenience, and adherence, which favors less invasive administration routes and limits the upside potential for injectables. Nevertheless, in clinical situations requiring rapid onset, predictable systemic exposure, or where medical resources are constrained, injectable formulations continue to offer functional advantages, preventing a sharp contraction in demand.
Key drivers include the ongoing need for reproductive health services, long-standing reliance on standardized treatment protocols, and clinical confidence in the reliability of injectable delivery in specific scenarios. In certain emerging markets and lower-tier healthcare settings, injectables remain attractive due to supply stability, clinical familiarity, and immediate therapeutic effect, providing a structural base of demand that supports market continuity.
At the same time, the market faces notable constraints. Declining patient acceptance of invasive treatments, concerns among healthcare providers regarding administration burden and safety, and tightening reimbursement and regulatory environments all exert downward pressure on usage. Moreover, continued improvements in oral and local delivery options are eroding the relative advantages of injectable therapies in some indications, resulting in a market that is structurally under pressure yet retains a degree of resilience.
This report studies the global Progesterone Injection production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Progesterone Injection and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Progesterone Injection that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Progesterone Injection total production and demand, 2021-2032, (K Units)
Global Progesterone Injection total production value, 2021-2032, (USD Million)
Global Progesterone Injection production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Progesterone Injection consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Progesterone Injection domestic production, consumption, key domestic manufacturers and share
Global Progesterone Injection production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Progesterone Injection production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Progesterone Injection production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Progesterone Injection market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Besins Healthcare, Organon, Pfizer, Sun Pharmaceutical Industries, Zydus Lifesciences, Cipla, Intas Pharmaceuticals, Zhejiang Xianju Pharmaceutical, Grand Pharmaceutical Group, Livzon, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Progesterone Injection market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Progesterone Injection Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Progesterone Injection Market, Segmentation by Type:
Originator Products
Branded Generics
Global Progesterone Injection Market, Segmentation by Formulation:
Oil-based Intramuscular Injection
Other
Global Progesterone Injection Market, Segmentation by Clinical Indication:
Luteal Phase Support in Assisted Reproductive Technology
Treatment of Luteal Phase Deficiency
Others
Global Progesterone Injection Market, Segmentation by Application:
Hospital
Clinic
Others
Companies Profiled:
Besins Healthcare
Organon
Pfizer
Sun Pharmaceutical Industries
Zydus Lifesciences
Cipla
Intas Pharmaceuticals
Zhejiang Xianju Pharmaceutical
Grand Pharmaceutical Group
Livzon
Key Questions Answered:
1. How big is the global Progesterone Injection market?
2. What is the demand of the global Progesterone Injection market?
3. What is the year over year growth of the global Progesterone Injection market?
4. What is the production and production value of the global Progesterone Injection market?
5. Who are the key producers in the global Progesterone Injection market?
6. What are the growth factors driving the market demand?
Progesterone Injection is typically formulated as an oil-based intramuscular injection, providing systemic progesterone supplementation for the treatment of luteal phase deficiency, luteal support in assisted reproductive technology (ART) cycles, and other clinical settings requiring rapid or stable plasma progesterone levels. It represents a long-established and clinically mature dosage form with widespread historical use. Key upstream inputs include pharmaceutical-grade progesterone API (steroidal hormone), vegetable or synthetic oil vehicles, antioxidants and stabilizers, injectable glass vials, rubber stoppers and aluminum seals, as well as sterile filtration and filling consumables; material costs are relatively low, while sterile manufacturing assurance, oil-phase stability and batch-to-batch consistency are critical quality control elements. Downstream customers mainly include OB-GYN hospitals, fertility clinics, and inpatient and outpatient departments of general hospitals, with continued utilization in regions where alternative dosage forms are less accessible or adherence considerations are secondary. On a due-diligence-grade estimation basis, global nameplate capacity for Progesterone Injection in 2025 is estimated at 0.62 billion units, with actual sales of approximately 0.51 billion units. Driven by extensive generic competition and regional pricing structures, the global average ex-factory price is estimated at USD 1.6 per unit. Overall industry gross margin is estimated at approximately 41%.
The market is characterized by a mature and highly standardized landscape, with supply dominated by multi-regional generic manufacturers and broad product availability. Pricing competition is well established, and clinical use is largely confined to defined settings within obstetrics, gynecology, and reproductive medicine. In many regions, injectable progesterone remains a recognized baseline option, although prescribing decisions have become increasingly selective as treatment pathways evolve. The growing adoption of alternative dosage forms has gradually reshaped the market structure, reducing the central role of injectable therapies without eliminating their presence.
Looking forward, the market is expected to remain broadly stable or experience gradual change rather than significant expansion. Healthcare systems are increasingly prioritizing patient comfort, convenience, and adherence, which favors less invasive administration routes and limits the upside potential for injectables. Nevertheless, in clinical situations requiring rapid onset, predictable systemic exposure, or where medical resources are constrained, injectable formulations continue to offer functional advantages, preventing a sharp contraction in demand.
Key drivers include the ongoing need for reproductive health services, long-standing reliance on standardized treatment protocols, and clinical confidence in the reliability of injectable delivery in specific scenarios. In certain emerging markets and lower-tier healthcare settings, injectables remain attractive due to supply stability, clinical familiarity, and immediate therapeutic effect, providing a structural base of demand that supports market continuity.
At the same time, the market faces notable constraints. Declining patient acceptance of invasive treatments, concerns among healthcare providers regarding administration burden and safety, and tightening reimbursement and regulatory environments all exert downward pressure on usage. Moreover, continued improvements in oral and local delivery options are eroding the relative advantages of injectable therapies in some indications, resulting in a market that is structurally under pressure yet retains a degree of resilience.
This report studies the global Progesterone Injection production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Progesterone Injection and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Progesterone Injection that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Progesterone Injection total production and demand, 2021-2032, (K Units)
Global Progesterone Injection total production value, 2021-2032, (USD Million)
Global Progesterone Injection production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Progesterone Injection consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Progesterone Injection domestic production, consumption, key domestic manufacturers and share
Global Progesterone Injection production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Progesterone Injection production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Progesterone Injection production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Progesterone Injection market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Besins Healthcare, Organon, Pfizer, Sun Pharmaceutical Industries, Zydus Lifesciences, Cipla, Intas Pharmaceuticals, Zhejiang Xianju Pharmaceutical, Grand Pharmaceutical Group, Livzon, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Progesterone Injection market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Progesterone Injection Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Progesterone Injection Market, Segmentation by Type:
Originator Products
Branded Generics
Global Progesterone Injection Market, Segmentation by Formulation:
Oil-based Intramuscular Injection
Other
Global Progesterone Injection Market, Segmentation by Clinical Indication:
Luteal Phase Support in Assisted Reproductive Technology
Treatment of Luteal Phase Deficiency
Others
Global Progesterone Injection Market, Segmentation by Application:
Hospital
Clinic
Others
Companies Profiled:
Besins Healthcare
Organon
Pfizer
Sun Pharmaceutical Industries
Zydus Lifesciences
Cipla
Intas Pharmaceuticals
Zhejiang Xianju Pharmaceutical
Grand Pharmaceutical Group
Livzon
Key Questions Answered:
1. How big is the global Progesterone Injection market?
2. What is the demand of the global Progesterone Injection market?
3. What is the year over year growth of the global Progesterone Injection market?
4. What is the production and production value of the global Progesterone Injection market?
5. Who are the key producers in the global Progesterone Injection market?
6. What are the growth factors driving the market demand?
Table of Contents
103 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World Manufacturers Competitive Analysis
- 4 United States VS China VS Rest of the World
- 5 Market Analysis by Type
- 6 Market Analysis by Formulation
- 7 Market Analysis by Clinical Indication
- 8 Market Analysis by Application
- 9 Company Profiles
- 10 Industry Chain Analysis
- 11 Research Findings and Conclusion
- 12 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
